Short Interest in AirSculpt Technologies, Inc. (NASDAQ:AIRS) Expands By 12.1%

AirSculpt Technologies, Inc. (NASDAQ:AIRS) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 2,040,000 shares, an increase of 12.1% from the November 15th total of 1,820,000 shares. Based on an average daily volume of 169,600 shares, the short-interest ratio is currently 12.0 days. Currently, 16.7% of the company’s stock are short sold.

AirSculpt Technologies Stock Performance

Shares of NASDAQ AIRS opened at $5.68 on Monday. The stock has a market capitalization of $328.77 million, a P/E ratio of -40.57 and a beta of 1.64. The firm’s 50-day moving average price is $6.37 and its two-hundred day moving average price is $5.03. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.80. AirSculpt Technologies has a 52-week low of $2.92 and a 52-week high of $9.20.

AirSculpt Technologies (NASDAQ:AIRS) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The firm had revenue of $42.55 million during the quarter, compared to the consensus estimate of $42.49 million. AirSculpt Technologies had a negative net margin of 4.13% and a positive return on equity of 2.22%. During the same quarter in the prior year, the business earned ($0.01) earnings per share. As a group, sell-side analysts forecast that AirSculpt Technologies will post 0.08 earnings per share for the current year.

Analysts Set New Price Targets

Separately, BTIG Research initiated coverage on shares of AirSculpt Technologies in a research note on Thursday, October 17th. They issued a “neutral” rating for the company.

Insider Buying and Selling

In other news, CEO Dennis Dean sold 24,510 shares of AirSculpt Technologies stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $6.54, for a total transaction of $160,295.40. Following the sale, the chief executive officer now directly owns 582,052 shares of the company’s stock, valued at approximately $3,806,620.08. The trade was a 4.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 78.77% of the stock is owned by corporate insiders.

Institutional Trading of AirSculpt Technologies

Institutional investors have recently modified their holdings of the company. Barclays PLC grew its stake in shares of AirSculpt Technologies by 227.0% in the 3rd quarter. Barclays PLC now owns 19,100 shares of the company’s stock worth $97,000 after purchasing an additional 13,259 shares during the last quarter. Geode Capital Management LLC raised its position in shares of AirSculpt Technologies by 6.4% during the third quarter. Geode Capital Management LLC now owns 355,540 shares of the company’s stock worth $1,803,000 after purchasing an additional 21,339 shares during the period. Vanguard Group Inc. boosted its position in shares of AirSculpt Technologies by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 576,038 shares of the company’s stock valued at $3,537,000 after purchasing an additional 5,606 shares during the period. Finally, SW Investment Management LLC increased its stake in AirSculpt Technologies by 5.0% in the 2nd quarter. SW Investment Management LLC now owns 4,500,000 shares of the company’s stock worth $18,000,000 after purchasing an additional 213,677 shares in the last quarter. Institutional investors and hedge funds own 91.54% of the company’s stock.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc, together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure.